Hisamitsu Pharmaceutical has filed a patent for a patch that prevents the degradation of asenapine or its salt. The patch includes an adhesive layer containing asenapine, a basic amino acid (lysine, arginine, or histidine), and a pharmaceutically acceptable salt. GlobalData’s report on Hisamitsu Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Hisamitsu Pharmaceutical, Microneedles for transdermal drug delivery was a key innovation area identified from patents. Hisamitsu Pharmaceutical's grant share as of September 2023 was 43%. Grant share is based on the ratio of number of grants to total number of patents.
A recently filed patent (Publication Number: US20230310340A1) describes a patch for the treatment of schizophrenia. The patch consists of an adhesive layer on a backing, with the adhesive layer containing an adhesive base, asenapine or a pharmaceutically acceptable salt thereof, and at least one basic amino acid selected from lysine, arginine, and histidine or a pharmaceutically acceptable salt thereof. The adhesive base can be a rubber adhesive base, an acrylic adhesive base, or a silicone adhesive base. The content of the basic amino acid or its salt in the adhesive layer is between 0.01 mass % and 7 mass % of the total mass of the adhesive layer.
The patent also discloses a method for suppressing the degradation of asenapine or its salt in the patch. The method involves adding at least one basic amino acid selected from lysine, arginine, and histidine or a pharmaceutically acceptable salt thereof to the adhesive layer, which is applied on a backing. The adhesive base used in the method can be a rubber adhesive base, an acrylic adhesive base, or a silicone adhesive base. The content of the basic amino acid or its salt in the adhesive layer is between 0.01 mass % and 7 mass % of the total mass of the adhesive layer.
Furthermore, the patent describes a method for treating schizophrenia using the patch. The method involves applying the patch to a patient in need of treatment. The patch contains an adhesive layer on a backing, with the adhesive layer comprising an adhesive base, asenapine or a pharmaceutically acceptable salt thereof, and at least one basic amino acid selected from lysine, arginine, and histidine or a pharmaceutically acceptable salt thereof. The adhesive base can be a rubber adhesive base, an acrylic adhesive base, or a silicone adhesive base. The content of the basic amino acid or its salt in the adhesive layer is between 0.01 mass % and 7 mass % of the total mass of the adhesive layer.
In summary, the patent presents a patch and methods for its use in the treatment of schizophrenia. The patch contains an adhesive layer with specific components, including asenapine or its salt and at least one basic amino acid. The addition of the basic amino acid helps to suppress the degradation of asenapine in the patch, ensuring its effectiveness in treating schizophrenia.
To know more about GlobalData’s detailed insights on Hisamitsu Pharmaceutical, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
